PTGX
Protagonist Therapeutics, Inc
$109.78
-0.01%
$7.1B
No data for this timeframe.
Vol
Market Cap$7.1B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders50 funds
Inst. Value$6.0B
Inst. Activity25 buys / 13 sells
Insider Activity0B / 13S
Insider Net $-$35.1M
Reddit Sentiment50° Neutral
SEC Reports6
Recent Activity
Jun 12, 2026
SEC
In Q3 2024, 15 institutions accumulated $54.4M in PTGX (net +$43.4M) while 13 sellers reduced holdings by $267.9M, drive
INST-CLUSTER — Impact 5/10
Jun 10, 2026
Insider
Waddill William D. acquired via exercise 3,000 shares
Director @ $11.80 ($35.4K)
Jun 10, 2026
Insider
Waddill William D. sold 9,000 shares
Director @ $107.68 ($969.1K)
May 29, 2026
Insider
Waddill William D. acquired via exercise 9,000 shares
Director @ $11.80 ($106.2K)
May 15, 2026
SEC
Protagonist Therapeutics CEO Dinesh Patel sold $7.5M worth of stock on May 12, 2026, following a $600K sale by Director
CLUSTER — Impact 4/10
May 12, 2026
SEC
CEO Dinesh Patel and Director Bryan Giraudo sold a combined $11.7M in open-market shares within a week of PTGX reporting
CLUSTER — Impact 5/10
Inst.
Invesco Ltd. — ADD
2,164,670 shares ($228.2M)
Inst.
BANK OF AMERICA CORP — ADD
1,295,434 shares ($136.5M)
Price Targets
$118.69
+8.1% upside
Buy
Current $109.78
Low $100.00
Median $118.00
High $137.00
13 analysts
$100.00
$137.00
Analyst Ratings
7Strong Buy
11Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 6, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| May 6, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Apr 15, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| Apr 7, 2026 | Clear Street | MAINTAIN | Buy → Buy |
| Mar 19, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.77 ▲ +25.3% | $-0.55 — $2.79 | 422% YoY | 10 |
| Next Q | $2.24 ▲ +113.6% | $-0.40 — $3.67 | 461% YoY | 9 |
| Current FY | $4.17 ▲ +50.5% | $-1.00 — $5.88 | 304% YoY | 12 |
| Next FY | $-0.68 ▼ -57.7% | $-2.33 — $2.01 | -116% YoY | 11 |
Latest Reports
MIXED
INST-CLUSTER
5/10
In Q3 2024, 15 institutions accumulated $54.4M in PTGX (net +$43.4M) while 13 sellers reduced holdings by $267.9M, drive
Jun 12, 2026
NEUTRAL
CLUSTER
4/10
Protagonist Therapeutics CEO Dinesh Patel sold $7.5M worth of stock on May 12, 2026, following a $600K sale by Director
May 15, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| BlackRock, Inc. | $1.0B | — |
| FARALLON CAPITAL MANAGEMENT LLC | $669.2M | — |
| RTW INVESTMENTS, LP | $533.2M | — |
| WELLINGTON MANAGEMENT GROUP LLP | $379.4M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Waddill William | M | $35.4K |
| Jun 10, 2026 | Waddill William | SELL | $969.1K |
| May 29, 2026 | Waddill William | M | $106.2K |
| May 29, 2026 | Waddill William | SELL | $896.8K |
| May 12, 2026 | PATEL DINESH | M | $1.6M |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $6.0B total value (56,755,306 shares) as of 2026-Q1. Top holders: NOMURA, BlackRock,, FARALLON. Net buying activity: 25 institutions added/increased vs 13 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | BlackRock, Inc. | 9,779,369 | $1.0B | 17.2% | — |
| 3 | FARALLON CAPITAL MANAGEMENT LLC | 6,348,906 | $669.2M | 11.2% | — |
| 4 | RTW INVESTMENTS, LP | 5,059,053 | $533.2M | 8.9% | — |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 3,599,644 | $379.4M | 6.3% | ADD +66.2% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3,481,211 | $366.9M | 6.1% | — |
| 7 | STATE STREET CORP | 3,116,749 | $328.5M | 5.5% | — |
| 8 | JANUS HENDERSON GROUP PLC | 2,891,527 | $304.9M | 5.1% | DOUBLED +140.7% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 2,805,896 | $295.7M | 4.9% | — |
| 10 | Invesco Ltd. | 2,164,670 | $228.2M | 3.8% | ADD +38.1% |
| 11 | CITADEL ADVISORS LLC | 1,551,900 | $163.6M | 2.7% | — |
| 12 | Woodline Partners LP | 1,414,173 | $149.1M | 2.5% | — |
| 13 | BANK OF AMERICA CORP /DE/ | 1,295,434 | $136.5M | 2.3% | ADD +49.3% |
| 14 | JENNISON ASSOCIATES LLC | 1,072,011 | $113.0M | 1.9% | DOUBLED +223.7% |
| 15 | MORGAN STANLEY | 1,018,222 | $107.3M | 1.8% | — |
| 16 | Hood River Capital Management LLC | 829,285 | $87.4M | 1.5% | NEW |
| 17 | GOLDMAN SACHS GROUP INC | 778,945 | $82.1M | 1.4% | — |
| 18 | DRIEHAUS CAPITAL MANAGEMENT LLC | 720,928 | $76.0M | 1.3% | TRIM -34.4% |
| 19 | FMR LLC | 661,997 | $69.8M | 1.2% | — |
| 20 | MARSHALL WACE, LLP | 628,075 | $66.2M | 1.1% | TRIM -38.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Invesco Ltd. | ADD | 1,567,840 | 2,164,670 | +38.1% | $228.2M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 867,580 | 1,295,434 | +49.3% | $136.5M | 2026-Q1 |
| JENNISON ASSOCIATES LLC | DOUBLED | 331,164 | 1,072,011 | +223.7% | $113.0M | 2026-Q1 |
| Hood River Capital Management LLC | NEW | — | 829,285 | — | $87.4M | 2026-Q1 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | TRIM | 1,099,170 | 720,928 | -34.4% | $76.0M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 1,024,925 | 628,075 | -38.7% | $66.2M | 2026-Q1 |
| Clearbridge Investments, LLC | ADD | 489,842 | 621,820 | +26.9% | $65.5M | 2026-Q1 |
| Alyeska Investment Group, L.P. | DOUBLED | 199,523 | 593,197 | +197.3% | $62.5M | 2026-Q1 |
| Rubric Capital Management LP | NEW | — | 427,998 | — | $45.1M | 2026-Q1 |
| Neuberger Berman Group LLC | ADD | 98,473 | 141,441 | +43.6% | $14.9M | 2026-Q1 |
| FRANKLIN RESOURCES INC | ADD | 76,442 | 137,871 | +80.4% | $14.5M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | NEW | — | 101,299 | — | $10.7M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | ADD | 46,454 | 87,858 | +89.1% | $9.3M | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 37,346 | 83,197 | +122.8% | $8.8M | 2026-Q1 |
| Rafferty Asset Management, LLC | TRIM | 63,661 | 46,752 | -26.6% | $4.9M | 2026-Q1 |
| ASSETMARK, INC | DOUBLED | 285 | 46,442 | +16195.4% | $4.9M | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 5,723 | 40,376 | +605.5% | $4.3M | 2026-Q1 |
| Allspring Global Investments Holdings, LLC | DOUBLED | 3,985 | 29,916 | +650.7% | $3.1M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 13,270 | 27,260 | +105.4% | $2.9M | 2026-Q1 |
| EXCHANGE TRADED CONCEPTS, LLC | TRIM | 35,039 | 23,773 | -32.2% | $2.5M | 2026-Q1 |
| BAMCO INC /NY/ | ADD | 8,300 | 15,000 | +80.7% | $1.6M | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 327 | 13,202 | +3937.3% | $1.4M | 2026-Q1 |
| NOMURA HOLDINGS INC | TRIM | 17,521 | 10,479 | -40.2% | $1.1M | 2026-Q1 |
| Allianz Asset Management GmbH | TRIM | 13,000 | 9,600 | -26.2% | $1.0M | 2026-Q1 |
| GLENMEDE TRUST CO NA | TRIM | 12,755 | 9,235 | -27.6% | $973.4K | 2026-Q1 |
6 unique insiders with 26 transactions. Net insider value: -$35.1M ($0.00 bought, $35.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Waddill William D. | Director | EXERCISE | 3,000 | $11.80 | $35.4K |
| Jun 10, 2026 | Waddill William D. | Director | SELL | 9,000 | $107.68 | $969.1K |
| May 29, 2026 | Waddill William D. | Director | EXERCISE | 9,000 | $11.80 | $106.2K |
| May 29, 2026 | Waddill William D. | Director | SELL | 9,000 | $99.64 | $896.8K |
| May 12, 2026 | PATEL DINESH V PH D | President and CEO | EXERCISE | 75,000 | $21.58 | $1.6M |
| May 12, 2026 | PATEL DINESH V PH D | President and CEO | SELL | 75,000 | $100.12 | $7.5M |
| May 12, 2026 | PATEL DINESH V PH D | President and CEO | EXERCISE | 75,000 | $21.58 | $1.6M |
| May 12, 2026 | PATEL DINESH V PH D | President and CEO | SELL | 75,000 | $100.12 | $7.5M |
| May 8, 2026 | Giraudo Bryan | Director | SELL | 6,000 | $100.00 | $600.0K |
| May 7, 2026 | Giraudo Bryan | Director | EXERCISE | 24,000 | $6.45 | $154.8K |
| May 7, 2026 | Giraudo Bryan | Director | SELL | 36,000 | $100.14 | $3.6M |
| Apr 23, 2026 | PATEL DINESH V PH D | President and CEO | GIFT | 1,460 | — | — |
| Apr 20, 2026 | Ali Asif | Chief Financial Officer | SELL | 1,750 | $105.47 | $184.6K |
| Mar 26, 2026 | Ali Asif | Chief Financial Officer | EXERCISE | 19,500 | $19.19 | $374.2K |
| Mar 26, 2026 | Ali Asif | Chief Financial Officer | SELL | 24,765 | $104.24 | $2.6M |
| Mar 26, 2026 | SELICK HAROLD E | Director | EXERCISE | 24,000 | $12.88 | $309.1K |
| Mar 26, 2026 | SELICK HAROLD E | Director | SELL | 24,000 | $105.00 | $2.5M |
| Mar 26, 2026 | MOLINA ARTURO MD | Chief Medical Officer | EXERCISE | 15,000 | $8.04 | $120.6K |
| Mar 26, 2026 | MOLINA ARTURO MD | Chief Medical Officer | SELL | 15,000 | $104.79 | $1.6M |
| Mar 25, 2026 | PATEL DINESH V PH D | President and CEO | SELL | 54,641 | $101.00 | $5.5M |
| Mar 25, 2026 | PATEL DINESH V PH D | President and CEO | EXERCISE | 54,641 | $8.58 | $468.8K |
| Mar 24, 2026 | PATEL DINESH V PH D | President and CEO | EXERCISE | 59 | $8.58 | $506.22 |
| Mar 24, 2026 | PATEL DINESH V PH D | President and CEO | SELL | 59 | $101.00 | $6.0K |
| Mar 23, 2026 | PATEL DINESH V PH D | President and CEO | GIFT | 50,000 | — | — |
| Feb 6, 2026 | Waddill William D. | Director | SELL | 20,000 | $83.68 | $1.7M |
| Feb 6, 2026 | Waddill William D. | Director | EXERCISE | 20,000 | $8.31 | $166.2K |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 2 mixed, 2 neutral. Avg impact: 5.3/10.
MIXED
INST-CLUSTER
5/10
In Q3 2024, 15 institutions accumulated $54.4M in PTGX (net +$43.4M) while 13 sellers reduced holdin
Jun 12, 2026
NEUTRAL
CLUSTER
4/10
Protagonist Therapeutics CEO Dinesh Patel sold $7.5M worth of stock on May 12, 2026, following a $60
May 15, 2026
NEUTRAL
CLUSTER
5/10
CEO Dinesh Patel and Director Bryan Giraudo sold a combined $11.7M in open-market shares within a we
May 12, 2026
BEARISH
144
5/10
CEO Dinesh Patel filed a Form 144 to sell 75,000 shares (~$7.76M at the filing date) via J.P. Morgan
May 12, 2026
BULLISH
8-K
7/10
Protagonist Therapeutics reported Q1 2026 revenue of $56.4M and GAAP EPS of $0.05, significantly exc
May 5, 2026
MIXED
8-K
6/10
Protagonist Therapeutics reported a significant year-over-year decline in revenue and a net loss for
Feb 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (90% buy). Based on 20 analysts: 7 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$118.69 mean target
+8.1% upside
Buy (1.38)
$100.00 Low
$137.00 High
| Metric | Value |
|---|---|
| Current Price | $109.78 |
| Target Low | $100.00 |
| Target Mean | $118.69 |
| Target Median | $118.00 |
| Target High | $137.00 |
| # Analysts | 13 |
| Recommendation | Buy (1.38) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.77 | $-0.55 | $2.79 | 422.1% | +25.3% | 4↑ 2↓ | $0.2B | 3710.4% | 10 |
| Next Q 2026-09-30 |
$2.24 | $-0.40 | $3.67 | 460.5% | +113.6% | 3↑ 3↓ | $0.2B | 4249.3% | 9 |
| Current FY 2026-12-31 |
$4.17 | $-1.00 | $5.88 | 303.6% | +50.5% | 6↑ 2↓ | $0.5B | 1006.6% | 12 |
| Next FY 2027-12-31 |
$-0.68 | $-2.33 | $2.01 | -116.4% | -57.7% | 3↑ 2↓ | $0.2B | -68.6% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.772 | |
| 7d ago | $1.728 | +0.044 |
| 30d ago | $1.414 | +0.357 |
| 60d ago | $1.414 | +0.357 |
| 90d ago | $1.313 | +0.459 |
12 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 6, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| May 6, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 15, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Apr 7, 2026 | Clear Street | MAINTAIN | Buy | Buy |
| Mar 19, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Mar 19, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 19, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 19, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 3, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Feb 26, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Feb 26, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Feb 2, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Jan 30, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Dec 17, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 11 | 2 | 0 | 0 | 90% | |
| May 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Mar 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Feb 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Jan 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 25, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 25, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 12, 2026
short_interest
FTD: PTGX — 10,792 shares ($1.1M) failed to deliver
Settlement: 20260512, Price: $103.50, FTD Value: $1,116,972, PROTAGONIST THERAPEUTICS INC C
May 8, 2026
short_interest
FTD: PTGX — 31,241 shares ($3.1M) failed to deliver
Settlement: 20260508, Price: $98.85, FTD Value: $3,088,172.85, PROTAGONIST THERAPEUTICS INC C
May 4, 2026
earnings_calendar
PTGX Q1 2026 Earnings After Market Close — 2026-05-04
Apr 23, 2026
short_interest
FTD: PTGX — 27,974 shares ($3.0M) failed to deliver
Settlement: 20260423, Price: $105.55, FTD Value: $2,952,655.7, PROTAGONIST THERAPEUTICS INC C
Apr 22, 2026
short_interest
FTD: PTGX — 167,374 shares ($17.7M) failed to deliver
Settlement: 20260422, Price: $105.89, FTD Value: $17,723,232.86, PROTAGONIST THERAPEUTICS INC C
Apr 21, 2026
short_interest
FTD: PTGX — 5,489 shares ($0.6M) failed to deliver
Settlement: 20260421, Price: $105.47, FTD Value: $578,924.83, PROTAGONIST THERAPEUTICS INC C
Apr 17, 2026
short_interest
FTD: PTGX — 20,360 shares ($2.1M) failed to deliver
Settlement: 20260417, Price: $103.73, FTD Value: $2,111,942.8, PROTAGONIST THERAPEUTICS INC C
Mar 4, 2026
short_interest
FTD: PTGX — 9,288 shares ($0.8M) failed to deliver
Settlement: 20260304, Price: $91.30, FTD Value: $847,994.4, PROTAGONIST THERAPEUTICS INC C
Feb 27, 2026
short_interest
FTD: PTGX — 6,327 shares ($0.6M) failed to deliver
Settlement: 20260227, Price: $88.39, FTD Value: $559,243.53, PROTAGONIST THERAPEUTICS INC C